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Liverﬁbrosisandcirrhosisareamajorcauseofmorbidityandmortalityworldwide.Developmentoftheﬁbroticscarisanoutcome
ofchronicliverdiseasesofvaryingaetiologiesincludingalcoholicliverdisease(ALD)nonalcoholicliverdisease(NAFLD)including
non-alcoholicsteatohepatitis(NASH)viralhepatitisBandC(HBV,HCV).Thecriticalstepinthedevelopmentofscarisactivation
ofhepatic stellatecells(HSCs),whichbecome theprimarysourceofextracellular matrix.Aberrantapoptosisisafeatureofchronic
liver diseases and is associated with worsening stages of ﬁbrosis. However, apoptosis is also the main mechanism promoting the
resolution of ﬁbrosis, and spontaneous or targeted apoptosis of HSC is associated with regression of ﬁbrosis in animal models
and patients with chronic liver disease. Given the importance of apoptosis in disease progression and resolution, there is much
interest in precisely delineating the mechanisms involved and also developing biomarkers that accurately reﬂect the underlying
pathogenesis. Here, we review the mechanisms driving apoptosis in development of liver disease and use of apoptosis -related
biomarkers to aid in clinical diagnosis. Finally, we will also examine the recent literature regarding new insights into mechanisms
involved in apoptosis of activated HSCs as possible method of ﬁbrosis regression.
1.Introduction
Liver injury leading to ﬁbrosis occurs in response to a variety
of insults including alcohol, viral hepatitis, steatosis and
insulin resistance, autoimmune disease, excessive deposition
of iron or copper, and congenital abnormalities. Fibrosis
is the consequence of an overactive wound healing process
in response to the injury [1]. A key step in this process
is activation and proliferation of HSC from periportal and
perisinusoidal areas [2]. Under normal conditions, the HSC
resides in the space of Disse in a quiescent phenotype storing
retinoids including vitamin A [3]. Upon liver injury HSCs
transform to an active phenotype, positive for alpha smooth
muscle actin (α-SMA) and producing excessive ﬁbrillar
collagens, proinﬂammatory cytokines including IL-6, IL-
8, MCP1, and inhibitors of matrix proteases. Initially, this
process is driven by an inﬂammatory response and results
in a controlled deposition of extracellular matrix; however, if
the underlying insult persists, there is an excessive deposition
of extracellular matrix including cross-linking of collagen
and impairment of hepatocyte regeneration [4].
In chronic liver diseases, liver cell death is a prominent
feature and correlates with worsening ﬁbrosis [5, 6]. The
cell death can occur by one of two mechanisms: necrosis
or apoptosis. Apoptosis is a highly synchronised procedure
requiring cellular ATP; conversely death by necrosis is ATP
independent. In recent years, it has been suggested that
both apoptosis and necrosis can occur in response to a
single initiating factor; however, the ultimate fate of the cell
is thought to depend largely on the severity of the initial
damage signal. It is likely that other forms of cell death
such as autophagy (self digestion) [7], paraptosis [8], ne-
croptosis [9], and oncosis [10] also play an important role in
ﬁbrogenesis; however, in this paper, we will focus speciﬁcally
on apoptosis.
2.Apoptosisor ProgrammedCellDeath(PCD)
Apoptosis is a normal physiological process and is charac-
terised by a well-synchronised sequence of morphological
events. The dying cell undergoes nuclear and cytoplasmic2 International Journal of Hepatology
condensation, blebbing of the plasma membrane, and
eventually breaking apart into membrane-enclosed particles
termed apoptotic bodies containing intact organelles, as
well as portions of the nucleus [11, 12]. These apoptotic
bodies are recognised, engulfed, and degraded by profes-
sional phagocytes, innate immune cells, and HSC [13].
Within the liver, the major cell type to eliminate apoptotic
bodies is the resident liver macrophage, the Kupﬀer cell. In
comparison, necrosis, is a pathological or accidental mode
of cell death, characterised by irreversible swelling of the
cytoplasm and distortion of organelles, including mitochon-
dria [14]. Eventually there is loss of membrane integrity
resulting in cell rupture and release of cellular contents.
Necrosis occurs when cells are subjected to toxic stimuli
such as hyperthermia, metabolic poisons, and direct cell
trauma. Several important biochemical markers of apoptosis
have been identiﬁed, including nuclear DNA fragmentation,
activation of aspartate-speciﬁc proteases known as caspases
and cell surface externalization of phosphatidylserine (PS)
residues, expression of several death ligand TNFs, FasL, or
overexpression of death receptors including TRADD, Fas,
and DR5 [15]. Although cell death may transpire in the
absence of caspases [16], the characteristic morphological
features that deﬁne apoptosis are dependency of caspase
activationandcleavageofspeciﬁccellularproteinsor“death”
substrateswithinthecell.Apoptosismaythereforebeviewed,
in biochemical terms, as a caspase-mediated form of cell
death. At present, two major pathways that link apoptosis
have been identiﬁed: (a) intrinsic or mitochondrial and (b)
extrinsic or death receptor related.
2.1. Mitochondrial or Intrinsic Pathway of Apoptosis. The
intrinsic pathway involves the regulation of apoptosis by
mitochondria and is characterized by the release of mi-
tochondrial intermembrane space proteins including
cytochrome c, apoptosis-inducing factor (AIF), second mi-
tochondrial activator of caspases (Smac), direct IAP
binding protein with low pI (DIABLO), endonuclease
G, and Omi/HtrA2 into the cytosol [17]. Cytosolic
cytochrome c subsequently activates a multiprotein complex
referred to as the apoptosome, which in turn leads to
cleavage of procaspase-9 and downstream eﬀector caspases
(e.g., caspase-3), resulting in cell death. As such, the
mitochondria have emerged as a novel target for anticancer
chemotherapy. This target is based on the observation that
several conventional and experimental chemotherapeutic
agents promote the permeabilization of mitochondrial
membranes in cancerous cells to initiate the release of
apoptogenic mitochondrial proteins. This ability to en-
gagemitochondrial-mediatedapoptosisdirectlyusingchem-
otherapy may be responsible for overcoming aberrant
apoptosis regulatory mechanisms commonly encountered in
cancerous cells. Interestingly, several putative cancer chem-
opreventive agents also possess the ability to trigger
apoptosis in transformed, premalignant, or malignant cells
in vitro via mitochondrial membrane permeabilization [18].
This process may occur through the regulation of Bcl-2
family members or by the induction of the mitochondrial
permeability transition. Thus, by exploiting endogenous
mitochondrial-mediated apoptosis inducing mechanisms,
certain chemopreventive agents may be able to block the
progression of premalignant cells to malignant cells or the
dissemination of malignant cells to distant organ sites as
means of modulating carcinogenesis in vivo.
2.2. Death Receptor or Extrinsic Pathway of Apoptosis. The
extrinsic pathway is triggered by ligation of death receptors,
such as CD95 or the agonistic TRAIL receptors TRAIL-
R1 and TRAIL-R2, by their cognate ligands or agonistic
antibodies, which results in receptor trimerization, clus-
tering of the receptors death domains, and recruitment
of adaptor molecules (e.g., Fas-associated death domain
FADD) through homophilic interaction mediated by the
death domain [19]. FADD in turn recruits caspase-8 to
the activated CD95 receptor to form the CD95 death-
inducing signaling complex (DISC). Oligomerization of
caspase-8uponDISCformationdrivesitsactivationthrough
self-cleavage. Caspase-8 then activates downstream eﬀector
caspases such as caspase-3 [20]. Links between the receptor
andthe mitochondrial pathwayexist atdiﬀerent levels. Upon
death receptor triggering, activation of caspase-8 results
in cleavage of proapoptotic Bid protein, a Bcl-2 family
protein with a BH3 domain only, whose truncated form
is inserted into the mitochondrial outer membrane and
promotes cytochrome c release and consequent activation
of the apoptosome, thereby initiating a mitochondrial
ampliﬁcation loop [17]. In addition, cleavage of caspase-6
downstream of mitochondria can feed back to the receptor
pathway by cleaving caspase-8 [21]. The idea to speciﬁcally
target death receptors to trigger apoptosis in tumour cells is
attractive for cancer therapy, as death receptors have a direct
link to the cell death machinery. Also, apoptosis upon death
receptor triggering is considered to occur independently of
the p53 tumour suppressor gene, which is impaired in the
majority of human tumours [22].
3. Apoptosis in Liver Disease
Apoptosis can occur in response to viral infection, and
exposure to any kind of hepatocarcinogen, excessive alcohol
consumption or due to genetic mutations. The liver resident
cells express high levels of cell-death-associated receptors,
for instance hepatocytes, cholangiocytes, activated stellate
cells, and Kupﬀer cells all express Fas. High expression of
the Fas receptor not only helps to maintain liver homeostasis
but also helps to eliminate virally infected cells of liver by
the immunocytes [23]. Fas/FasL signalling has been largely
implicated in liver pathophysiology but the mitochondrial
intrinsic pathways are also involved in liver homeostasis. Bid,
one of the BH3 subfamily proteins, is cleaved by caspase-8,
and the truncated Bid then translocates to the mitochondria
where it activates the intrinsic apoptosis pathway. It has been
shown that bid-deﬁcient mice are resistant to Fas-induced
hepatocellular apoptosis [24]. These studies implicate both
extrinsic and intrinsic apoptotic pathways in maintaining
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3.1. Viral Hepatitis. There are seven diﬀerent types of viral
hepatitis, among them hepatitis B (HBV) and hepatitis C
(HCV)arethemajorcauseofhepaticcelldestructionleading
to chronic hepatitis, ﬁbrosis and increased risk of formation
of hepatocellular carcinoma [25]. It is now well established
that cytotoxic T cells induce apoptosis of virally infected
hepatocytes via Fas/FasL and perforin-mediated pathways
[26].FasL-expressinginﬁltratedmononuclearcellsarefound
in the hepatitis-C-infected patients [27]. Conversely, failure
of immune cells to eliminate virally infected hepatocytes
leads to viral persistence and immune surveillance causing
chronic hepatitis and initiating ﬁbrogenesis. Invivo silencing
by small interfering RNA (siRNA) duplexes targeting the
gene Fas protects mice from liver failure and ﬁbrosis in
t w om o d e l so fa u t o i m m u n eh e p a t i t i s[ 16]. In addition to
viral-induced damage, host factors such as the presence of
steatosis are associated with increased hepatocyte apoptosis
in patients with HCV infection. Additionally, hepatocyte
apoptosis in patients with steatosis correlates with grade
of ﬁbrosis, implicating a direct link between apoptosis and
ﬁbrosis [28].
3.2. Alcoholic Steatohepatitis. Excessive alcohol consumption
maylead to changesin fatmetabolism, causechronic inﬂam-
mation,andovertimepromotethedevelopmentofachronic
hepatitis and ﬁbrosis called alcoholic steatohepatitis (ASH)
[29]. Hepatocyte ballooning and apoptotic hepatocytes are
the common features in the liver of patients with ASH [30].
Excessive hepatocyte apoptosis stimulates inﬂammation and
results in the production of proinﬂammatory cytokines
and reactive oxygen species by innate immune cells [31].
Additionally, oxidative stress-induced hepatocyte apoptosis
is one of the consequences of acute alcohol injury [32].
Defects in endocytosis leading to accumulation of apoptotic
bodies followedbyinﬂammation mayalsoplayanimportant
roleinalcoholicliverinjury.Ithasbeenfoundthatinethanol
induced impairment receptor mediated endocytosis model
defects in asialoglycoprotein receptor, which lead to defective
uptake of apoptotic bodies causing severe liver injury [33].
CYP2E1 is one of the key markers upregulated in alcoholic
liver disease [34]. CYP2E1 is an isoform of cytochrome
p450 related to free radical generation. Increased free radical
production causes DNA damage and lipid peroxidation
increasing the severity of the disease by inducing oxidative
stress induced hepatocytic damage [35].
3.3. NAFLD and NASH. Apoptotic death of hepatocytes is
a common feature of nonalcoholic steatohepatitis and is
associated with ﬁbrosis [5]. Increased expression of death
r e c e p t o r sl i k eF a sa n dT N F - Rh a sb e e nf o u n di nm o s to f
the NASH patients. Both extrinsic and intrinsic apoptotic
pathways are involved in NASH-induced hepatocyte death
[36, 37]. Caspase-3 and caspase-7 are activated with disease
progression and subsequently cleave a major ﬁlamentous
protein known as cytokeratin-18 (CK-18) [38]. Endoplasmic
reticulum stress-induced apoptosis is a feature of multiple
diseases including cystic ﬁbrosis, diabetes, and Parkinson’s
and prion-related diseases [39] and may be an important
mechanism in NAFLD and NASH. The presence of hepatic
steatosis is associated with an increase in ER stress and a
subsequent increase in hepatocyte apoptosis and liver injury
[40].
3.4. Liver Fibrosis. Liver ﬁbrosis is the consequence of chron-
ic liver injury. After toxic exposure hepatocytes undergo
apoptosis and hepatic stellate cells migrate to the site of
injury to engulf the apoptotic bodies. This engulfment pro-
motes activation of the hepatic stellate cells to hepatic myoﬁ-
broblasts, and in their activated state these cells promote
deposition of extracellular matrix and scar formation in the
liver. Recently it has been demonstrated that hepatocyte-
speciﬁc disruption of Bcl-xL induces continuous hepatocyte
apoptosis and ﬁbrogenesis [41]. Several proinﬂammatory
cytokines including IL-6, TNF-α induce unresolved hep-
atocytic inﬂammation. The proﬁbrogenic cytokine TGF-β
is secreted by the immune cells gathered at site of injury
to phagocytose the apoptotic bodies, further fuelling the
inﬂammatory and ﬁbrogenic reaction [42].
3.5. Hepatocellular Carcinoma. Hepatocellular carcinoma
(HCC) is the consequence of exposure to carcinogen or envi-
ronmental pollutants, chronic viral infection, and obesity
andisthe3rdmajorcauseofcancerdeathworldwide.HCCis
a slow progressing disease. During theinitiation phaseof this
disease the balance between apoptosis and cell proliferation
of hepatic cells is disrupted and favours proliferation,
whereas hepatocytes undergo high levels of hepatocytic
cell death. In response to this injury, innate immune cells
migrate to the site of damage and release a plethora of
proinﬂammatory cytokines and free radicals generating an
inﬂammatory microenvironment, which promotes cancer
progression. After chronic exposure to rounds of liver injury
and inﬂammation hepatocytes develop mechanisms to evade
apoptotic death; this results in the accumulation of damaged
hepatocytes that eventually become HCC. These mecha-
nisms include the persistent downregulation of proapoptotic
molecules and upregulation of antiapoptotic proteins. Fas
receptor and Fas ligand are highly expressed on hepatocytes;
however, levels of these proteins are diminished during the
disease progression [43]. Concurrently, decreased expression
of other downstream molecules from the Fas family includ-
ing FADD (Fas Associated death domain) and FLICE have
been observed during HCC development [44]. Loss of other
death receptors including TRAIL-R has also been linked to
neoplastic growth and reduced apoptosis in HCC [45]. Anti-
apoptotic factor, brain and reproductive organ-expressed
protein (BRE), is a death-receptor-associated protein and is
upregulated in HCC. BRE binds to tumor necrosis factor
receptor-1 and Fas, and in cell lines it has been shown to
attenuate apoptosis by inhibiting t-Bid-induced activation of
the mitochondrial pathway [46]. Normal liver homeostasis is
maintained by a balance of proapoptotic and antiapoptotic
genes but in the majority of cases of HCC it has been
shown that there is an overexpression of antiapoptotic genes.
This imbalance can be caused by diﬀerent mechanisms.
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virus inhibits apoptosis by overexpressing Bcl-xL [47]. One
of the important antiapoptotic proteins XIAP (inhibitor of
caspases)helpstobypassapoptoticpathwayinHCCprogres-
sion [48]. Growth arrest DNA damage-inducible gene 45β
(GADD45beta) regulates apoptotic cell death in response to
DNA damage. Downregulation of GADD45beta has been
observed in HCC [49]. Another important regulator of liver
cancer progression is the tumour suppressor gene p53. This
gene is activated when there is DNA damage, but, in most
cases of HCC, the p53 gene is mutated. Kraus and colleagues
postulated that this was a result of oxidative stress and
that this provided a link between chronic inﬂammation and
genomic changes observed in precancerous cells [50].
4. Biomarkers of Apoptosis in LiverDisease
One of the most promising biomarkers of apoptosis is CK-
18. Serum levels of CK-18 are markedly increased in patients
with NASH compared with patients with steatosis or normal
biopsies [51, 52]. Additionally, serum levels of uncleaved
CK-18 are able to distinguish between simple steatosis and
NASH. More recently, in a prospective study examining the
utility of apoptosis biomarkers to predict ﬁbrosis in patients
withNASH,bothfulllengthandcaspase-cleavedCK-18were
able to discriminate diﬀerent stages of ﬁbrosis with healthy
controls [53]. Patients with HCV infections also have higher
levels of serum CK-18 correlating with serum transferase
a c t i v i t y ;h o w e v e r ,s o m ep a t i e n t sh a de l e v a t e ds e r u mC K - 1 8
with normal transaminases, suggesting that CK-18 may be
an earlier maker of liver damage. The utility of serum CK-
18 levels in discriminating diﬀerent stages of HCV and ALD,
for example, needs to be studied further but it may provide a
minimally invasive method of assessing the underlying liver
injury.
5.IncreasedApoptosis of HepatocytesMay
DirectlyContribute to Fibrogenesis
There is mounting evidence that suggests phagocytosis
of apoptotic bodies by hepatic stellate cells may directly
stimulate ﬁbrogenesis [54]. Although liver macrophages
are thought to be the main cell involved in phagocytosis,
endothelial cells and ﬁbroblasts have been demonstrated to
clear apoptotic bodies [42, 54]. Both HSCs and Kupﬀer cells
(KC) express the phosphatidyl serine receptor suggesting
that both cell types are able to internalize apoptotic bodies.
Engulfment of apoptotic bodies by KC is associated with a
marked increase in proﬁbrogenic factors including TRAIL,
TNF-α,FasL,andTGFβ1mRNAexpression 24hoursfollow-
ing exposure to apoptotic bodies derived from hepatocytes.
Kupﬀer cells isolated from bile duct ligated (BDL) mice
also show an increase in the expression of TRAIL-associated
ligandscomparedwithsham-operatedanimals.Additionally,
depletion of KC from BDL mice was associated with a
signiﬁcant reduction in hepatocyte apoptosis and liver injury
and a concurrent reduction in α-SMA and col1A1 mRNA
expression [42]. Increasein the expression of TRAILmarkers
on KC may be suitable biomarkers for pathogenic hepatocyte
apoptosis. Subsequent perpetuation of hepatocyte apoptosis
is associated with an increase in inﬂammation and liver
ﬁbrosis. This suggests that engulfment of apoptotic bodies
mayprolongthecycleofliverinjuryandthattargetingofKCs
maybe a viable therapeutic option in cholestasis to reduce
liver ﬁbrosis.
Phagocytosis of hepatocyte-derived apoptotic bodies by
stellate cells has also been implicated in ﬁbrogenesis. Apop-
totic bodies express phosphatidyl serine, which acts as an
engulfment signal. Canbay and colleagues found that Lx-
1 cells (human hepatic stellate cell line) express the phos-
phatidyl serine (PS) receptor and that these cells show a
signiﬁcant increase in TGF-β1 and Col1a1 mRNA expression
after 48-hour incubation with apoptotic bodies. Blocking of
engulfment of apoptotic bodies by Nocodazole abrogates the
further increase in α-SMA and TGF-β1 suggesting that the
increase in ﬁbrogenic nature of the HSC was speciﬁcally as a
consequence of apoptotic body engulfment [54].
6. Apoptosis and Reversalof LiverFibrosis
6.1. Clinical Evidence for Reversal of Fibrosis Apoptosis. Until
recently, transplantation was considered the only viable
treatment option for cirrhosis and severe forms of liver
disease [55]. However, there is a growing body of clinical evi-
dencethatsuggestsﬁbrosisissomewhatreversible.Successful
treatment of underlying viral infection in patients with HCV
and HBV is associated with regression of liver ﬁbrosis and, in
some instances, reversal of cirrhosis upon liver biopsy [56–
58]. Similarly in cholestatic-type liver diseases, regression
of liver ﬁbrosis was reported after biliary drainage in
patients with stenosis of the common bile duct. Additionally,
abstinence from alcohol [59] and weight loss have also been
associated with an improvement in histological analysis of
ﬁbrosis.
6.2. Experimental Evidence for Spontaneous Apoptosis-Me-
diated Regression of Apoptosis. Summarised in Figure 1 there
is a considerable experimental evidence suggesting that
apoptosis of activated HSCs is the main mechanism associ-
ated with regression of ﬁbrosis. There are two seminal papers
that show spontaneous regression of ﬁbrosis mediated by
apoptosis. Firstly, Iredale and colleagues discovered that in
rats treated with carbon tetrachloride to induce signiﬁcant
liver ﬁbrosis, α-SMA-positive cells, ﬁbrosis and hydroxy
proline content returned to an almost histologically normal
state 28 days following cessation of liver injury. Importantly,
dual staining for TUNEL and α-SMA showed spontaneous
resolutionofﬁbrosiswasassociatedwithanincreaseinapop-
tosis of nonparenchymal α-SMA-positive cells [60]. This
hypothesishasbeensubsequentlyconﬁrmedinanadditional
in vivo model of ﬁbrosis. Issa and colleagues ligated the bile
duct of rats for 21 days to induce ﬁbrosis, then biliodigestive
anastomosis was performed and rats were allowed to recover
for 45 days. There was a 5-fold decrease in α-SMA-positive
myoﬁbroblasts with rapid apoptosis indicated by TUNEL-
positive cells two days after anastomosis [61].International Journal of Hepatology 5
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Figure 1: Mechanisms for targeting apoptosis to treat liver disease and cause ﬁbrosis regression.
This method of deleting collagen-producing HSCs has
been exploited in animal models to reduce ﬁbrosis. The
potent fungal metabolic toxin, Gliotoxin, induces apoptosis
ofactivatedratHSCsinvitroandinvivoandthisisassociated
with a signiﬁcant reduction in the number of activated
HSCs and a reduction in the thickness of the bridging
ﬁbrosis and serum ALT without impairment of hepatocyte
regeneration [62]. While HSCs are sensitive to apoptosis at
low concentrations of Gliotoxin (1.5uM), hepatocytes are
resistant to apoptosis however they will undergo necrosis
at high concentrations. Originally thought to act through
an NF-kB-dependent mechanism, it is likely that Gliotoxin
induces apoptosis via a rapid accumulation of glutathione,
which is abrogated by pretreatment with thiol redox active
agents such as PDTC [63].
There is mounting evidence suggesting that directly
targeting NF-κB is a viable therapeutic option in liver
disease. Activated HSCs have high levels of NF-κBa c t i v i t y
and an increase in basal expression of NF-κB-regulated
antiapoptotic proteins including IL-6, Bcl-2 family mem-
bers and GADD45β and A20. Blunt inhibition of NF-κB-
regulated antiapoptotic genes by treatment with a proteo-
some inhibitor prevented induction of antiapoptotic genes
and caused apoptosis. Treatment of BDL mice with borte-
zomib was associated with a reduction in α-SMA-positive
HSCs and ﬁbrosis [64]. IKK2 inhibition with pharmaco-
logical agent AS602868 is also associated with attenuated
ﬁbrosis progression in mice with dietary-induced NASH
and thought to work by limiting the accumulation of hep-
atic steatosis and hepatocyte apoptosis [65]. Sulphasalazine
is a drug used commonly in humans for treatment of
inﬂammation-type disorders including rheumatoid arthritis
and inﬂammatory bowel disease [66]. Sulphasalazine acts to
block NF-κB activity by blocking the activity of inhibitor
of κB (IkB) kinases α and β (IKKα and IKKβ) resulting in
a downregulation of NF-κB targets. In vivo administration
of sulphasalazine to rats with CCl4-induced liver injury was
associated with stimulation of HSC apoptosis (and NF-κB-
regulated antiapoptotic gene GADD45β)a n dac o n c u r r e n t
reduction in α-SMA-positive myoﬁbroblasts and Col1a1
[67].
Novo and colleagues noted in cirrhotic human liver that
Bcl-2 was highly expressed in α-SMA-positive myoﬁbrob-
lasts, and this staining was particularly strong in areas at
the interface between ﬁbrotic septa and regenerative nodule
[68]. Upstream from Bcl-2, constitutive expression of P-
Ser536-RelA is a key feature of activated human HSCs and
is in part regulated in an autocrine fashion by angiotensin
II. Inhibition of the angiotensin II receptor (AT1) and/or
treatment with ACE inhibitor Captopril was associated
with loss of P-Ser536-positive HSCs, a reduction in α-
SMA-positive HSCs, and ﬁbrosis regression. Importantly,
in patients with hepatitis C viral infection who upon liver
biopsywerefoundtohaveconstitutiveexpressionofP-Ser536,
treatment with Losartan was associated with regression of
ﬁbrosis. Those patients who did not have P-Ser536 expressed
on biopsy were not sensitive to Losartan therapy and did
not undergo regression of ﬁbrosis. Constitutive expression
of P-Ser536 may be an important tissue biomarker to assess
whether a patient is likely to respond to similar therapy.
Directly targeting hepatocyte apoptosis to reduce liver
ﬁbrosis may also be a viable strategy. Male db/db mice
fed a methionine/choline-deﬁcient diet (MCD) to induce
NASHandliverﬁbrosisandsubsequentlytreatedwithapan-
caspase inhibitor, VX-166, showed a reduction in α-SMA-
positive HSCs and had reduced expression of Col1a1 mRNA
and reduced ﬁbrosis, conﬁrmed with Sirius red staining.
However, serum ALT levels were similar in mice fed MCD
alone, suggesting that there was no improvement in liver
injurydespitesomereductioninsteatosis,reductioninTNF-
α production, and formation of nitrotyrosine adducts [69].6 International Journal of Hepatology
Treatment of an injured liver (especially in the presence
of ongoing injury) with an apoptosis inhibitor may be
detrimentalandpreventthenormalremovalofpremalignant
hepatocytes and proﬁbrogenic myoﬁbroblasts.
7.Paracrine-MediatedApoptosis ofHSC
Under normal conditions, nitric oxide exerts a paracrine
eﬀect on HSC; however, in incidences of severe liver ﬁbrosis
andcirrhosiseNOSgenerationisimpaired.Thisisassociated
with the typical features of liver disease. In vitro, NO donor
SNP is associated with an increase in primary rat HSC
apoptosis, and overexpression of NO in Lx2 cells sensitized
them to apoptosis caused by stimulation with TRAIL [70].
However, the mechanism by which apoptosis occurs is
unclear. Langer and colleagues found a signiﬁcant decrease
inmitochondrialmembranepotential(ΔΨm)aftertreatment
with SNP, which was not abrogated by pretreatment with
pan-caspase inhibitors. It is possible that NO-mediated
nitrosylation of the active site of caspase-3 impairs cleavage
resulting in caspase independent apoptosis [16]. Enhancing
the intracellular oxidative stress further potentiated apopto-
sis induced by SNP. Importantly, SNP is already approved for
usein human, and we awaitfurtherin vivo data to determine
if HSC apoptosis results in regression of ﬁbrogenesis.
8. miRNAs
miRNAs are small noncoding RNAs of 21–25 nucleotide
bases thought to regulate gene transcription posttranslation-
ally by changing the stability of mRNA through binding to
the 3  UTR [71]. (mechanism reviewed extensively in He,
Nature Reviews Genetics 2004) [72]. Activation of HSCs
is associated with a change in the expression proﬁle of
mRNAs including miR-16, -15b, -122, -128, -143, and -140
[73]. From this expression proﬁling, Guo and colleagues
then identiﬁed a critical role for miR-16 and miR-15b
in apoptosis. Transfection of miR-16 and miR-15b into
activated HSCs concurrently reduced Bcl2 expression and
increased expression of caspase-3, 8, and 9, and this was
accompanied by a subsequent increase in apoptosis in
activated HSCs [73]. Additionally, transfection of activated
HSCs with miR-16 was associated with a reduction in
cyclin D1. This was paralleled by a subsequent reduction
in proliferation and increased apoptosis [73]. miR-29b is
inducible in Lx2 cells by IFN-α in a dose-dependent fashion
and was found to suppress Col1a1. This may be part of the
mechanism whereby patients with HCV show a regression
of ﬁbrosis after treatment with IFN-α. Similarly, inhibition
of 27a and 27b has been shown to aid the return of HSC
to a lipid-containing phenotype by reducing the expression
of retinoid X receptor α and was also associated with a
subsequent decrease in proliferation. However, Col1a1 and
α-SMA expression levels did not change, nor was there
any signiﬁcant induction of apoptosis [74]. Venugopal and
colleagues found a downregulation of miR-150 and miR-194
in hepatic stellate cells isolated from the ﬁbrotic livers from
BDL rats compared with sham operated animals. In vitro
overexpression of miR-150 and miR-194 caused decreased
stellate cell activation, inhibition of cell proliferation, and
reduction in α-SMA expression and Col1a1 levels, possibly
by inhibition of c-myb (miR-150) and rac (miR-194);
however, there was no signiﬁcant increase in apoptosis [75].
Similarly, a decrease in miR-29 expression level is associated
with Col1a1 accumulation in activated HSCs. Targeting
miRNAs may provide a mechanism to cause apoptosis of
activated HSCs. As yet, no serum biomarkers are available
to measure miRNA activity; however, tissue biomarkers may
be of use to determine if HSCs are reprogrammed to avoid
apoptosis.
9.TLR9Activation
The injured liver is exposed to high levels of danger-
associatedmolecularpatterns(DAMPs)thatactasstimulifor
members of the Toll-like receptor (TLR) family. Wantanabe
et al. hypothesised that debris from apoptotic hepatocytes
could modulate the activation of HSC via TLR9 signalling.
They showed that expression of the proﬁbrogenic genes
Col1a1 and TGFβ1 in LX2 cells and primary mouse HSCs
wasincreaseduponexposuretohepatocyteDNAorcytidine-
phosphate-guanosine (CPG) oligonucleotides, the ligand
for TLR9. Administration of a TLR9 antagonist prevented
induction of these genes and also inhibited platelet-derived-
growth-factor (PDGF) dependent HSC chemotaxis, an eﬀect
also observed in HSCs deﬁcient for either TLR9 or its down-
stream adaptor molecule MyD88. The authors concluded
that DNA released from damaged hepatocytes acts as a signal
to “halt” HSC migration, retaining them at the site of injury
and promote scar formation [76]. TLR9-mediated activation
of HSCs may confer resistance to apoptosis and further
promoting ﬁbrogenesis. The role of TLR9 and DAMPS in
liver disease needs further investigation.
10.ExtracellularMatrix
The link between extracellular matrix and apoptosis of HSCs
has previously been reviewed extensively; see Elsharkaway
Apoptosis 2005 [77]a n dBenyon Seminars in Liver Disease
2001 [78]. In brief, increased activity in matrix degradation
e n z y m e si sak e ys t e pi nr e s o l u t i o no fﬁ b r o s i s[ 56]. In
vitrotreatment of HSCs with recombinant MMP9 stimulates
apoptosis [79], which can be abrogated by pretreatment with
an inhibitor [80]. Additionally, under conditions of recovery,
interstitial MMPs have an increased collagenolytic activity,
degrading the extracellular matrix and leaving the HSC
more susceptible to undergo apoptosis [81]. Overexpression
of MMP inhibitor TIMP-1 in mice treated with CCl4,
was associated with an inability to undergo apoptosis of
activated HSC and no concurrent resolution of ﬁbrosis
[82]. The mechanism of action by which TIMP-1 acts to
inhibit apoptosis is via activating phosphatidylinositol 3-
kinase and ERKs resulting in downregulation of caspases
[83]. These studies suggest that in addition to secreting
Col1A1, activated HSCs also secrete matrix-related enzymes
that act to protect the HSC against proapoptotic signals.International Journal of Hepatology 7
Serum levels of MMPs and TIMPs on their own and in
combination with liver stiﬀness tests, enhanced liver ﬁbrosis
(ELF), and so forth are useful biomarkers to predict the
existence and extent of liver disease and are a useful tool
for monitoring resolution. TIMP-1 along with hyaluronic
acid (HA) and the N-terminal pro-peptide of collagen type
III are the key serum markers of underlying ﬁbrosis on
the ELF panel. This panel has been validated in a large
cohort of patients with NAFLD and NASH [84, 85]a n d
has been reported to have better diagnostic capabilities than
other standard panel of biomarkers including MELD and
the Mayo Risk (R) score in instances of primary biliary
cirrhosis [86]. To date, most research has been centered
around the use of biomarkers in instances of chronic liver
disease; however, a recent publication by Dechene and
colleagues suggests that they may have some utility in acute
liver failure (ALF). Both TIMP-1 (4.2-fold) and TIMP-2
(1.6-fold) were found to be signiﬁcantly increased in the
sera of ALF patients compared with control individuals.
Additionally, in the group of patients with ALF, MMP-
1 and MMP-2 were signiﬁcantly upregulated more than
two fold, suggesting that these biomarkers of apoptosis and
protease activity may be a useful indicator of underlying
ﬁbrogenesis. The increase in serum markers was paralleled
by an increase in Col1a1 and α-SMA observed on liver
biopsy. This research also identiﬁed a correlation between
serum biomarkers of apoptosis (TIMP-1 and M65) and liver
stiﬀness measured by FibroScan. Additionally, over a one-
week observation period, there was a reduction in liver
stiﬀness that corresponded to a reduction in serum markers
of apoptosis and ﬁbrogenesis [87]. These studies highlight
the important relationship between extracellular matrix and
apoptosis identifying ﬁbrogenesis and the potential for using
apoptosis biomarkers as part of a panel of markers to
longitudinally monitor activity during recovery period.
11. Endogenous CannabinoidReceptors
Lipidic cannabinoid ligands and receptors CB1 and CB2
have an important role in the pathogenesis of chronic
liver injury. Under normal conditions, the endocannabinoid
receptors are undetectable; however, expression is slowly
increased upon stellate cell activation and remains elevated
in later stages of liver disease [88–90]. CB2 receptors are
locatedinHSCs;however,CB1receptorsarealsoupregulated
in vascular endothelium [90]. Protein expression of the
CB1 receptor is increased in cirrhotic livers compared
with normal human liver and appears to be expressed in
nonparenchymal cells located proximal to the ﬁbrotic septa.
Immunohistochemical analysis of CB1 receptor showed co-
localizationwith α-SMA-positive cellsandactivatedcultured
myoﬁbroblasts express higher levels of the receptor com-
pared with quiescent. In mice injured with CCl4 or who
underwent BDL, selective inhibition of CB1 with antagonist
SR141716A decreases TGFβ and α-SMA expression during
injury,andthiswasaccompaniedbya37%and41%decrease
in ﬁbrosis respectively. Additionally, in cannabinoid receptor
1 knockout mice (Cnr1−/−), there was a 30% and 35%
reduction in ﬁbrosis area in thioacetamide and BDL models
of ﬁbrosis. In culture, Cnr1−/− HSC are more susceptible to
apoptosis mediated by serum deprivation, and there was a
64% increase in apoptosis of α-SMA-positive cells in these
animals.
EndocannabinoidsmediateapoptosisthroughCB1,CB2,
and also transient receptor potential vanilloid 1 (TRPV1)
which acts as the receptor for anandamide (AEA). The
mechanismofactionofAEAiswellunderstoodandreviewed
more extensively by Siegmund et al., 2008. HSCs but
importantly not hepatocytes are sensitive to apoptosis by
both endocannabinoids AEA and 2-AG. Anandamide is the
main endogenous agonist against a group of lipid mediators
termed endocannabinoid and acts on the cannabinoid
receptor CB1 and CB2. Anandamide (AEA) selectively kills
HSC by necrosis but not hepatocytes, and this occurs in-
dependently of CB1 and CB2 and VR1 receptors. Sieg-
mund and colleagues noted that treatment of activated
HSCs with AEA induced necrosis via a Ca2+- and ROS-
dependent fashion and that pretreatment with glutathione
or a Ca2+ chelator (EDTA, BAPTA-tetrapotassium salt, or
BAPTA-AM) signiﬁcantly abrogated the eﬀects of AEA on
HSC necrosis. Additionally, preincubation with membrane
cholesterol depleting agent prevented necrosis, suggesting
that AEA may not be speciﬁc to CB receptors. While causing
necrosis of HSC, hepatocytes appear not to be susceptible.
This compound needs assessing in vivo and may prove to be
a valuable therapeutic to target ﬁbrosis [91].
12. Conclusions
Signiﬁcant progress has been made in our understanding of
the mechanisms of apoptosis and the relative contribution
apoptosis plays in disease progression. Pathophysiological
role of apoptosis is implicated in a number of liver diseases
andcontributesdirectlytoﬁbrogenesis.Serumbiomarkersof
hepatocyteapoptosishavebeenwellcharacterizedinNAFLD
and NASH and provide insight into disease severity. These
markers, particularly cleaved CK-18, prove to be sensitive
enough to distinguish between patients with simple steatosis
and more advanced stages of disease. Further clinical studies
are needed to determine CK-18 utility in other liver diseases.
While the prospect of treating patients with liver disease with
a pharmacological agent to cause the regression of ﬁbrosis is
exciting, further investigation is required into the long-term-
eﬃcacy.Blanketinhibitionofhepatocyteapoptosiswithpan-
caspase or proteosome inhibitors reduces ﬁbrosis; however,
it may not improve liver function. Further studies are needed
to determine the long-term eﬀect of these inhibitors on liver
function. Inhibition of the normal physiological process of
removing damaged hepatocytes may prove to be detrimental
and leave patients susceptible to developing hepatocellular
carcinomas.
Ideally, next-generation antiﬁbrotic therapies will target
apoptosis-inducing mechanisms speciﬁc for activated HSC
or beneﬁt from targeted delivery systems. New insights
into mechanisms of apoptosis have highlighted HSC spe-
ciﬁc involvement of NF-κB signaling, cannabinoid receptor8 International Journal of Hepatology
signaling, and miRNAs important in regulating apoptosis
and may provide further pharmacological targets. Perhaps
most importantly, HSC-speciﬁc biomarkers of apoptosis
may not only provide further clinically relevant information
regarding underlying disease but also predict the likelihood
of a patient’s response to therapy.
References
[1] S. L. Friedman, “Liver ﬁbrosis—from bench to bedside,” Jour-
nal of Hepatology, Supplement, vol. 38, no. 1, pp. S38–S53,
2003.
[2] M. Pinzani and K. Rombouts, “Liver ﬁbrosis: from the bench
to clinical targets,” Digestive and Liver Disease, vol. 36, no. 4,
pp. 231–242, 2004.
[3] S. L. Friedman, “Seminars in medicine of the Beth Israel
Hospital, Boston: the cellular basis of hepatic ﬁbrosis—
mechanisms and treatment strategies,” New England Journal
of Medicine, vol. 328, no. 25, pp. 1828–1835, 1993.
[4] S. L. Friedman, “Mechanisms of hepatic ﬁbrogenesis,” Gas-
troenterology, vol. 134, no. 6, pp. 1655–1669, 2008.
[5] A. E. Feldstein, A. Canbay, P. Angulo et al., “Hepatocyte
apoptosisandFasexpressionareprominentfeaturesofhuman
nonalcoholic steatohepatitis,” Gastroenterology, vol. 125, no. 2,
pp. 437–443, 2003.
[6] H. Jaeschke and J. J. Lemasters, “Apoptosis versus oncotic
necrosis in hepatic ischemia/reperfusion injury,” Gastroen-
terology, vol. 125, no. 4, pp. 1246–1257, 2003.
[7] T. Hidvegi, M. Ewing, P. Hale et al., “An autophagy-enhancing
drug promotes degradation of mutant α1-antitrypsin Z and
reduces hepatic ﬁbrosis,” Science, vol. 329, no. 5988, pp. 229–
232, 2010.
[8] M. Dodig and K. D. Mullen, “New mechanism of selective
killing of activated hepatic stellate cells,” Hepatology, vol. 38,
no. 4, pp. 1051–1053, 2003.
[9] H. Malhi and J. Gores G., “Liver cell death,” Molecular
Pathology of Liver Diseases, pp. 373–387, 2011.
[10] H. Malhi, G. J. Gores, and J. J. Lemasters, “Apoptosis and
necrosis in the liver: a tale of two deaths?” Hepatology, vol. 43,
no. 2, pp. S31–S44, 2006.
[11] T. Patel and G. J. Gores, “Apoptosis and hepatobiliary disease,”
Hepatology, vol. 21, no. 6, pp. 1725–1741, 1995.
[12] P. R. Galle, “Apoptosis in liver disease,” Journal of Hepatology,
vol. 27, no. 2, pp. 405–412, 1997.
[ 1 3 ]A .H .W y l l i e ,J .F .R .K e r r ,a n dA .R .C u r r i e ,“ C e l ld e a t h :t h e
signiﬁcance of apoptosis,” International Review of Cytology,
vol. 68, pp. 251–306, 1980.
[14] S. Sperandio, I. De Belle, and D. E. Bredesen, “An alternative,
nonapoptotic form of programmed cell death,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 97, no. 26, pp. 14376–14381, 2000.
[15] P. M. Chaudhary, M. Eby, A. Jasmin, A. Bookwalter, J. M.
U r r a y ,a n dL .H o o d ,“ D e a t hr e c e p t o r5 ,an e wm e m b e ro ft h e
TNFR family, and DR4 induce FADD- dependent apoptosis
and activate the NF-κBp a t h w a y , ”Immunity,v o l .7 ,n o .6 ,p p .
821–830, 1997.
[16] G. Kroemer and S. J. Martin, “Caspase-independent cell
death,” Nature Medicine, vol. 11, no. 7, pp. 725–730, 2005.
[17] G. van Loo, X. Saelens, M. van Gurp, M. MacFarlane, S.
J. Martin, and P. Vandenabeele, “The role of mitochondrial
factors in apoptosis: a Russian roulette with more than one
bullet,” Cell Death and Diﬀerentiation, vol. 9, no. 10, pp. 1031–
1042, 2002.
[18] G. Kroemer and J. C. Reed, “Mitochondrial control of cell
death,” Nature Medicine, vol. 6, no. 5, pp. 513–519, 2000.
[19] N. Hail, “Mitochondria: a novel target for the chemopreven-
tion of cancer,” Apoptosis, vol. 10, no. 4, pp. 687–705, 2005.
[20] A. Ashkenazi, “Targeting death and decoy receptors of the
tumour-necrosis factor superfamily,” Nature Reviews Cancer,
vol. 2, no. 6, pp. 420–430, 2002.
[21] V.CowlingandJ.Downward,“Caspase-6isthedirectactivator
of caspase-8 in the cytochrome c-induced apoptosis pathway:
absolute requirement for removal of caspase-6 prodomain,”
Cell Death and Diﬀerentiation, vol. 9, no. 10, pp. 1046–1056,
2002.
[22] S. Fulda and K. M. Debatin, “Signaling through death recep-
tors in cancer therapy,” Current Opinion in Pharmacology, vol.
4, no. 4, pp. 327–332, 2004.
[23] W. A. Faubion and G. J. Gores, “Death receptors in liver
biology and pathobiology,” Hepatology, vol. 29, no. 1, pp. 1–
4, 1999.
[24] X. M. Yin, K. Wang, A. Gross et al., “Bid-deﬁcient mice are
resistanttoFas-inducedhepatocellularapoptosis,”Nature,vol.
400, no. 6747, pp. 886–891, 1999.
[25] J. Fung, C. L. Lai, and M. F. Yuen, “Hepatitis B and C virus-
related carcinogenesis,” Clinical Microbiology and Infection,
vol. 15, no. 11, pp. 964–970, 2009.
[26] D. Kagi, B. Ledermann, K. Burki et al., “Cytotoxicity mediated
by T cells and natural killer cells is greatly impaired in
perforin-deﬁcientmice,” Nature,vol.369,no.6475,pp.31–37,
1994.
[27] N. Hiramatsu, N. Hayashi, K. Katayama et al., “Immunohis-
tochemical detection of Fas antigen in liver tissue of patients
with chronic hepatitis C,” Hepatology, vol. 19, no. 6, pp. 1354–
1359, 1994.
[28] M. J. Walsh, D. M. Vanags, A. D. Clouston et al., “Steatosis
and liver cell apoptosis in chronic hepatitis C: a mechanism
for increased liver injury,” Hepatology, vol. 39, no. 5, pp. 1230–
1238, 2004.
[29] Y.-G. Suh and W.-I. Jeong, “Hepatic stellate cells and innate
immunity in alcoholic liver disease,” World Journal of Gas-
troenterology, vol. 17, no. 20, pp. 2543–2551, 2011.
[30] S. Natori, C. Rust, L. M. Stadheim, A. Srinivasan, L. J. Burgart,
and G. J. Gores, “Hepatocyte apoptosis is a pathologic feature
of human alcoholic hepatitis,” Journal of Hepatology, vol. 34,
no. 2, pp. 248–253, 2001.
[31] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity,
Inﬂammation, and Cancer,” Cell, vol. 140, no. 6, pp. 883–899,
2010.
[32] I. Kurose, H. Higuchi, S. Miura et al., “Oxidative stress-
mediated apoptosis of hepatocytes exposed to acute ethanol
intoxication,” Hepatology, vol. 25, no. 2, pp. 368–378, 1997.
[33] C. A. Casey, S. M. L. Lee, R. Aziz-Seible, and B. L. McVicker,
“Impaired receptor-mediated endocytosis: its role in alcohol-
induced apoptosis,” Journal of Gastroenterology and Hepatol-
ogy, vol. 23, no. 1, pp. S46–S49, 2008.
[34] C.S.Lieber,“Alcoholicliverdisease:newinsightsinpathogen-
esis lead to new treatments,” Journal of Hepatology, vol. 32, no.
1, pp. 113–128, 2000.
[35] S. W. French, K. Wong, L. Jui, E. Albano, A. L. Hagbjork,
andM.Ingelman-Sundberg,“Eﬀect ofethanoloncytochrome
P450 2E1 (CYP2E1), lipid peroxidation, and serum protein
adduct formation in relation to liver pathology pathogenesis,”International Journal of Hepatology 9
Experimental and Molecular Pathology, vol. 58, no. 1, pp. 61–
75, 1993.
[36] A. E. Feldstein and G. J. Gores, “Apoptosis in alcoholic and
nonalcoholic steatohepatitis,” Frontiers in Bioscience, vol. 10,
no. 3, pp. 3093–3099, 2005.
[37] G. Musso, R. Gambino, G. Pacini, G. Pagano, M. Durazzo,
andM.Cassader,“Transcriptionfactor7-like2polymorphism
modulates glucose and lipid homeostasis, adipokine proﬁle,
and hepatocyte apoptosis in NASH,” Hepatology, vol. 49, no.
2, pp. 426–435, 2009.
[38] H. Bantel, P. Ruck, M. Gregor, and K. Schulze-Osthoﬀ,“ D e -
tection of elevated caspase activation and early apoptosis in
liver diseases,” European Journal of Cell Biology, vol. 80, no. 3,
pp. 230–239, 2001.
[39] R. J. Kaufman, “Orchestrating the unfolded protein response
in health and disease,” Journal of Clinical Investigation, vol.
110, no. 10, pp. 1389–1398, 2002.
[40] D. Wang, Y. Wei, and M. J. Pagliassotti, “Saturated fatty acids
promote endoplasmic reticulum stress and liver injury in rats
with hepatic steatosis,” Endocrinology, vol. 147, no. 2, pp. 943–
951, 2006.
[41] T. Takehara, T. Tatsumi, T. Suzuki et al., “Hepatocyte-speciﬁc
disruption of Bcl-xL leads to continuous hepatocyte apoptosis
and liver ﬁbrotic responses,” Gastroenterology, vol. 127, no. 4,
pp. 1189–1197, 2004.
[42] A. Canbay, A. E. Feldstein, H. Higuchi et al., “Kupﬀer cell
engulfment of apoptotic bodies stimulates death ligand and
cytokine expression,” Hepatology, vol. 38, no. 5, pp. 1188–
1198, 2003.
[43] K. Higaki, H. Yano, and M. Kojiro, “Fas antigen expression
and its relationship with apoptosis in human hepatocellular
carcinoma and noncancerous tissues,” American Journal of
Pathology, vol. 149, no. 2, pp. 429–437, 1996.
[44] E.C.Shin,J.S.Shin,J.H.Park,J.J.Kim,H.Kim,andS.J.Kim,
“Expression of Fas-related genes in human hepatocellular
carcinomas,” CancerLetters,vol.134,no.2,pp.155–162, 1998.
[45] N. Finnberg and W. S. El-Deiry, “TRAIL death receptors as
tumor suppressors and drug targets,” Cell Cycle, vol. 7, no. 11,
pp. 1525–1528, 2008.
[46] B. C. L. Chan, A. K. K. Ching, K. F. To et al., “BRE is an
antiapoptotic protein in vivo and overexpressed in human
hepatocellular carcinoma,” Oncogene, vol. 27, no. 9, pp. 1208–
1217, 2008.
[47] R. Sacco, T. Tsutsumi, R. Suzuki et al., “Antiapoptotic regula-
tionbyhepatitisCviruscoreproteinthroughup-regulationof
inhibitorofcaspase-activatedDNase,”Virology,vol.317,no.1,
pp. 24–35, 2003.
[48] Y. H. Shi, W. X. Ding, J. Zhou et al., “Expression of X-linked
inhibitor-of-apoptosis protein in hepatocellular carcinoma
promotes metastasis and tumor recurrence,” Hepatology, vol.
48, no. 2, pp. 497–507, 2008.
[49] W. Qiu, D. David, B. Zhou et al., “Down-regulation of
growth arrest DNA damage-inducible gene 45β expression is
associated with human hepatocellular carcinoma,” American
Journal of Pathology, vol. 162, no. 6, pp. 1961–1974, 2003.
[50] S. Kraus and N. Arber, “Inﬂammation and colorectal cancer,”
Current Opinion in Pharmacology, vol. 9, no. 4, pp. 405–410,
2009.
[ 5 1 ]A .W i e c k o w s k a ,N .N .Z e i n ,L .M .Y e r i a n ,A .R .L o p e z ,A .
J. McCullough, and A. E. Feldstein, “In vivo assessment of
liver cell apoptosis as a novel biomarker of disease severity in
nonalcoholic fatty liver disease,” Hepatology,v o l .4 4 ,n o .1 ,p p .
27–33, 2006.
[52] Z. M. Younossi, M. Jarrar, C. Nugent et al., “A novel diagnostic
biomarker panel for obesity-related nonalcoholic steatohep-
atitis(NASH),”ObesitySurgery,vol.18,no.11,pp.1430–1437,
2008.
[53] D. Joka, K. Wahl, S. Moeller et al., “Prospective biopsy-
controlled evaluation of cell death biomarkers for prediction
of liver ﬁbrosis and nonalcoholic steatohepatitis,” Hepatology,
vol. 55, no. 2, pp. 455–464, 2012.
[54] A. Canbay, P. Taimr, N. Torok, H. Higuchi, S. Friedman, and
G. J. Gores, “Apoptotic body engulfment by a human stellate
cell line is proﬁbrogenic,” Laboratory Investigation, vol. 83, no.
5, pp. 655–663, 2003.
[55] P. A. L. Bonis, S. L. Friedman, and M. M. Kaplan, “Is liver
ﬁbrosis reversible?” New England Journal of Medicine, vol. 344,
no. 6, pp. 452–454, 2001.
[56] M. J. P. Arthur, “Reversibility of liver ﬁbrosis and cirrhosis
following treatment for hepatitis C,” Gastroenterology, vol.
122, no. 5, pp. 1525–1528, 2002.
[57] T. Poynard, J. McHutchison, M. Manns et al., “Impact of
pegylated interferon alfa-2b and ribavirin on liver ﬁbrosis in
patients with chronic hepatitis C,” Gastroenterology, vol. 122,
no. 5, pp. 1303–1313, 2002.
[58] T. T. Chang, Y. F. Liaw, S. S. Wu et al., “Long-term ente-
cavir therapy results in the reversal of ﬁbrosis/cirrhosis and
continued histological improvement in patients with chronic
hepatitis B,” Hepatology, vol. 52, no. 3, pp. 886–893, 2010.
[59] A. Pares, J. Caballeria, and M. Bruguera, “Histological course
of alcoholic hepatitis. Inﬂuence of abstinence, sex and extent
of hepatic damage,” J o u r n a lo fH e p a t o l o g y ,v o l .2 ,n o .1 ,p p .
33–42, 1986.
[60] J. P. Iredale, R. C. Benyon, J. Pickering et al., “Mechanisms
of spontaneous resolution of rat liver ﬁbrosis: hepatic stellate
cell apoptosis and reduced hepatic expression of metallopro-
teinase inhibitors,” Journal of Clinical Investigation, vol. 102,
no. 3, pp. 538–549, 1998.
[61] R. Issa, E. Williams, N. Trim et al., “Apoptosis of hepatic
stellate cells: involvement in resolution of biliary ﬁbrosis and
regulation by soluble growth factors,” Gut,v o l .4 8 ,n o .4 ,p p .
548–557, 2001.
[62] M. C. Wright, R. Issa, D. E. Smart et al., “Gliotoxin stimulates
the apoptosis of human and rat hepatic stellate cells and
enhances the resolution of liver ﬁbrosis in rats,” Gastroenterol-
ogy, vol. 121, no. 3, pp. 685–698, 2001.
[63] J. G. Orr, V. Leel, G. A. Cameron et al., “Mechanism of action
of the antiﬁbrogenic compound gliotoxin in rat liver cells,”
Hepatology, vol. 40, no. 1, pp. 232–242, 2004.
[64] A. Anan, E. S. Baskin-Bey, S. F. Bronk, N. W. Werneburg, V. H.
Shah, and G. J. Gores, “Proteasome inhibition induces hepatic
stellate cell apoptosis,” Hepatology, vol. 43, no. 2, pp. 335–344,
2006.
[65] N.Beraza,Y.Malato,S.VanderBorghtetal.,“Pharmacological
IKK2 inhibition blocks liver steatosis and initiation of non-
alcoholic steatohepatitis,” Gut, vol. 57, no. 5, pp. 655–663,
2008.
[66] K. E. Donahue, G. Gartlehner, D. E. Jonas et al., “Systematic
review: comparative eﬀectiveness and harms of disease-
modifying medications for rheumatoid arthritis,” Annals of
Internal Medicine, vol. 148, no. 2, pp. 124–134, 2008.
[67] F. Oakley, V. Teoh, G. Ching-A-Sue et al., “Angiotensin II acti-
vates IκBk i n a s ep h o s p h o r y l a t i o no fR e l Aa tS e r 536 to promote
Myoﬁbroblast survival and liver ﬁbrosis,” Gastroenterology,
vol. 136, no. 7, pp. 2334–2344.e1, 2009.
[ 6 8 ]E .N o v o ,F .M a r r a ,E .Z a m a r ae ta l . ,“ O v e r e x p r e s s i o no f
Bcl-2 by activated human hepatic stellate cells: resistance to10 International Journal of Hepatology
apoptosis as a mechanism of progressive hepatic ﬁbrogenesis
in humans,” Gut, vol. 55, no. 8, pp. 1174–1182, 2006.
[69] R. P. Witek, W. C. Stone, F. G. Karaca et al., “Pan-caspase
inhibitor VX-166 reduces ﬁbrosis in an animal model of
nonalcoholic steatohepatitis,” Hepatology,v o l .5 0 ,n o .5 ,p p .
1421–1430, 2009.
[70] D. A. Langer, A. Das, D. Semela et al., “Nitric oxide promotes
caspase-independent hepatic stellate cell apoptosis through
the generation of reactive oxygen species,” Hepatology, vol. 47,
no. 6, pp. 1983–1993, 2008.
[71] X. Jiang, E. Tsitsiou, S. E. Herrick, and M. A. Lindsay,
“MicroRNAs and the regulation of ﬁbrosis,” FEBS Journal, vol.
277, no. 9, pp. 2015–2021, 2010.
[72] L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big
role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7,
pp. 522–531, 2004.
[73] C. J. Guo, Q. Pan, B. Jiang, G. Y. Chen, and D. G. Li, “Eﬀects
of upregulated expression of microRNA-16 on biological
propertiesofculture-activatedhepaticstellatecells,” Apoptosis,
vol. 14, no. 11, pp. 1331–1340, 2009.
[74] J. Ji, J. Zhang, G. Huang, J. Qian, X. Wang, and S. Mei, “Over-
expressed microRNA-27a and 27b inﬂuence fat accumulation
and cell proliferation during rat hepatic stellate cell activa-
tion,” FEBS Letters, vol. 583, no. 4, pp. 759–766, 2009.
[75] S. K. Venugopal, J. Jiang, T. H. Kim et al., “Liver ﬁbrosis causes
downregulation of miRNA-150 and miRNA-194 in hepatic
stellate cells, and their overexpression causes decreased stellate
cell activation,” American Journal of Physiology, vol. 298, no. 1,
pp. G101–G106, 2010.
[76] A. Watanabe, A. Hashmi, D. A. Gomes et al., “Apoptotic
hepatocyte DNA inhibits hepatic stellate cell chemotaxis via
toll-like receptor 9,” Hepatology, vol. 46, no. 5, pp. 1509–1518,
2007.
[77] A. M. Elsharkawy, F. Oakley, and D. A. Mann, “The role and
regulation of hepatic stellate cell apoptosis in reversal of liver
ﬁbrosis,” Apoptosis, vol. 10, no. 5, pp. 927–939, 2005.
[78] R. C. Benyon and M. J. P. Arthur, “Extracellular matrix
degradation and the role of hepatic stellate cells,” Seminars in
Liver Disease, vol. 21, no. 3, pp. 373–384, 2001.
[79] X. Zhou, F. R. Murphy, N. Gehdu, J. Zhang, J. P. Iredale,
a n dR .C .B e n y o n ,“ E n g a g e m e n to fαvβ3 integrin regulates
proliferation and apoptosis of hepatic stellate cells,” Journal of
Biological Chemistry, vol. 279, no. 23, pp. 23996–24006, 2004.
[80] F. R. Murphy, R. Issa, X. Zhou et al., “Inhibition of apop-
tosis of activated hepatic stellate cells by tissue inhibitor of
metalloproteinase-1 is mediated via eﬀects on matrix met-
alloproteinase inhibition. Implications for reversibility of liver
ﬁbrosis,” Journal of Biological Chemistry, vol. 277, no. 13, pp.
11069–11076, 2002.
[81] R. Issa, X. Zhou, C. M. Constandinou et al., “Sponta-
neous recovery from micronodular cirrhosis: evidence for
incomplete resolution associated with matrix cross-linking,”
Gastroenterology, vol. 126, no. 7, pp. 1795–1808, 2004.
[82] A. M. Preaux, M. P. D’Ortho, M. P. Bralet, Y. Laperche, and
P. Mavier, “Apoptosis of human hepatic myoﬁbroblasts pro-
motes activation of matrix metalloproteinase-2,” Hepatology,
vol. 36, no. 3, pp. 615–622, 2002.
[83] X. W. Liu, M. M. Bernardo, R. Fridman, and H. R. C.
Kim, “Tissue inhibitor of metalloproteinase-1 protects human
breast epithelial cells against intrinsic apoptotic cell death via
the focal adhesion kinase/phosphatidylinositol 3-kinase and
MAPKsignalingpathway,” JournalofBiologicalChemistry,vol.
278, no. 41, pp. 40364–40372, 2003.
[84] I. N. Guha, J. Parkes, P. Roderick et al., “Noninvasive markers
of ﬁbrosis in nonalcoholic fatty liver disease: validating the
European liver ﬁbrosis panel and exploring simple markers,”
Hepatology, vol. 47, no. 2, pp. 455–460, 2008.
[85] V. Nobili, J. Parkes, G. Bottazzo et al., “Performance of ELF
serum markers in predicting ﬁbrosis stage in pediatric non-
alcoholic fatty liver disease,” Gastroenterology, vol. 136, no. 1,
pp. 160–167, 2009.
[86] M. J. Mayo, J. Parkes, B. Adams-Huet et al., “Prediction
of clinical outcomes in primary biliary cirrhosis by serum
enhanced liver ﬁbrosis assay,” Hepatology, vol. 48, no. 5, pp.
1549–1557, 2008.
[87] A. Dechˆ ene, J. P. Sowa, R. K. Gieseler et al., “Acute liver failure
is associated with elevated liver stiﬀness and hepatic stellate
cell activation,” Hepatology, vol. 52, no. 3, pp. 1008–1016,
2010.
[88] B. Julien, P. Grenard, F. Teixeira-Clerc et al., “Antiﬁbrogenic
role of the cannabinoid receptor CB2 in the liver,” Gastroen-
terology, vol. 128, no. 3, pp. 742–755, 2005.
[89] D. Osei-Hyiaman, M. DePetrillo, P. Pacher et al., “Endo-
cannabinoid activation at hepatic CB1 receptors stimulates
fatty acid synthesis and contributes to diet-induced obesity,”
Journal of Clinical Investigation, vol. 115, no. 5, pp. 1298–1305,
2005.
[90] F.Teixeira-Clerc,B.Julien,P.Grenardetal.,“CB1cannabinoid
receptor antagonism: a new strategy for the treatment of liver
ﬁbrosis,” Nature Medicine, vol. 12, no. 6, pp. 671–676, 2006.
[91] S. V. Siegmund and R. F. Schwabe, “Endocannabinoids and
liver disease. II. Endocannabinoids in the pathogenesis and
treatmentofliverﬁbrosis,”AmericanJournalofPhysiology,vol.
294, no. 2, pp. G357–G362, 2008.